Evelo Biosciences (NASDAQ: EVLO)
Evelo Biosciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Evelo Biosciences Company Info
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Valuation
Earnings Transcripts
Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript
EVLO earnings call for the period ending June 30, 2022.
Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript
EVLO earnings call for the period ending December 31, 2021.
Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript
EVLO earnings call for the period ending September 30, 2021.
Evelo Biosciences, Inc. (EVLO) Q2 2021 Earnings Call Transcript
EVLO earnings call for the period ending June 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.